Innovate 2020: Stanford Retina Innovation Summit
| Overview / Abstract: |
Target Audience The educational design of this activity addresses the needs of practicing retina specialists, retinal fellows in training, and vitreoretinal surgeons involved in the treatment of patients with retinal disease. Statement of Need/Program Overview The Stanford Retina Innovation Summit will take place over 3 sessions. The summit series will focus exclusively on the latest, game-changing innovations in medical and surgical retina, imaging, and pharmacotherapy. Topics will include the latest retina pharmacotherapy clinical trials data, updates on artificial intelligence (AI) for diagnosis, advances in molecular surgery for the precision treatment of previously untreatable blinding diseases, and novel drug delivery technologies designed to improve patient care. The program will also focus on the role of imaging in determining new biomarkers for disease. Surgical innovation will be addressed in terms of new instrumentation, visualization enhancements, and image-guided surgery. This activity will showcase the journey and insights of leaders in retinal innovation, with the goal of equipping retina specialists to work collaboratively to solve unmet needs for our patients. Educational Objectives After completing this activity, the participant should be better able to: Examine the latest clinical data on emerging pharmacotherapeutics in retina This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and iVista Medical Education, Inc. Global is accredited by the ACCME to provide continuing medical education for physicians. Physician Credit Designation Global Education Group designates this enduring material for a maximum of 5.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Disclosures of Conflicts of Interest Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:Target Audience The educational design of this activity addresses the needs of practicing retina specialists, retinal fellows in training, and vitreoretinal surgeons involved in the treatment of patients with retinal disease. Statement of Need/Program Overview The Stanford Retina Innovation Summit will take place over 3 sessions. The summit series will focus exclusively on the latest, game-changing innovations in medical and surgical retina, imaging, and pharmacotherapy. Topics will include the latest retina pharmacotherapy clinical trials data, updates on artificial intelligence (AI) for diagnosis, advances in molecular surgery for the precision treatment of previously untreatable blinding diseases, and novel drug delivery technologies designed to improve patient care. The program will also focus on the role of imaging in determining new biomarkers for disease. Surgical innovation will be addressed in terms of new instrumentation, visualization enhancements, and image-guided surgery. This activity will showcase the journey and insights of leaders in retinal innovation, with the goal of equipping retina specialists to work collaboratively to solve unmet needs for our patients. Educational Objectives After completing this activity, the participant should be better able to: Examine the latest clinical data on emerging pharmacotherapeutics in retina This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and iVista Medical Education, Inc. Global is accredited by the ACCME to provide continuing medical education for physicians. Physician Credit Designation Global Education Group designates this enduring material for a maximum of 5.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Disclosures of Conflicts of Interest Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: |
|
Expiration |
Mar 09, 2022 |
|
Discipline(s) |
Physician CME |
|
Format |
Online |
|
Credits / Hours |
5.5 AMA PRA Category 1 Credit(s)™ |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
avid S. Boyer, MD Consultant/Independent Contractor: 4DMT,Acuela (C); Adverum (C, R); Aerie Pharmaceuticals (R); Aerpio (C, R); Aldeyra(C); Allegro (C); Allergan (C, R); Alzheon (C,); Apellis (C, R); Bayer (C); Chengdu Kanghong (C, R); Clearside Biomedical (C, R); EyePoint (C); Gemini Therapeutics (R); Galimedex (C,);Genentech/Roche (C, R); Graybug Vision (R); Gyroscope (C,);IONIS Pharmaceuticals (R); Hemera (C,); Iveric (C,); jCyte (C,);Kala (C,); KalVista (C,); Kodiak (C, R); Neurotech (R),NGM ©; Novartis (C, R); ONL Therapeutics (C); Ocular Therapeutics (C,); Ocunexus (C,); Opthea (R); Outlook Therapeutics (R); Oxurion (C); Recens Medical (C, R); Regeneron (C, R); Regenxbio (C, R); Roche (C,R); Santen (C, R); Santen (R,);Sciflor (C,R,) Stealth (C,R); Takeda (C) Thea (C,). Consultant/Independent Contractor: Regeneron , Genentech/Roche, Allergan, Novartis, Senju, Stealth, Boehringer Ingelheim, Ocular Therapeutics, Optos, Apellis, Kodiak, Celltrion, Horizon Therapeutics, Heidelberg, Annexon Biosciences, Lineage (BioTime), Chengdu Kanghong Biotechnology Co., Ltd, Regenxbio Grant/Research Support: Research funding from the NIH, NSF, Research to Prevent Blindness and Genentech Steve Charles, MD, FACS, FICS Consultant/Independent Contractor: Alcon Consultant/Independent Contractor: Regeneron, Genentech, Novartis, BI, Kodiak Sciences, Allergan, Asclepix, Graybug Consultant/Independent Contractor: Novartis; Zeiss; Roche; Regeneron; Genentech; Allegro; Aerpio; Allergan; Alcon; Thrombogenics; Leica Consultant/Independent Contractor: Aldeyra Therapeutics Consultant/Independent Contractor: Adverum, Aerie, AGTC, Alcon Laboratories, Inc., Aldeyra, Allegan, Apellis, Asclepix, Beaver-Visitec International, Inc, BioTime, Chengdu Kanghong Biotechnology, Covalent Medical, LLC, Genentech, Graybug, Gyroscope, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Notal, Ocular Therapeutics, ONL, Optovue, Inc., PanOptica, Regeneron Pharmaceuticals Inc., RegenXBio |
|
Sponsors / Supporters / Grant Providers |
Alcon Vision, LLC, EyePoint Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and REGENXBIO, Inc. |
|
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCME., Retina Free CE CME |
|